Rapamycin vs Metformin vs Reprogramming — What Actually Holds Up? 🔬

WISDOM IN PASSING — A late‑night conversation that makes longevity science clear, careful, and human. We explore three big ideas without hype: rapamycin and the mTOR pathway, metformin beyond diabetes, and partial cellular reprogramming (OSK) pursued by labs like Altos. No medical advice. Just honest context, plain language, and the questions that matter for healthspan, ethics, and real‑world tradeoffs. Inside, you will hear how researchers weigh evidence versus marketing, why human trials matter more than markers, and how to think about risk, fairness, and access when new therapies begin with narrow indications. If you want fewer buzzwords and more understanding, this conversation is for you. ❤️ Please support: https://tinyurl.com/44a93zrh 🎨 Other works by the creator: https://linktr.ee/AllOurWorks #LongevityScience #Rapamycin #Metformin #CellularReprogramming #AltosLabs #NorthernEnglishMaleCcBySa4 #AmyCcBySa4 #Healthspan